Compare

Oxford Nanopore Technologies /£ONT

1D1W1M3M6MYTD1Y5YMAX

About Oxford Nanopore Technologies

Oxford Nanopore Technologies plc, trading under the ticker ONT, operates in the biotechnology sector, focusing on the development of nanopore technology for DNA and RNA sequencing. Founded in 2005 and publicly listed, the company's innovative technology facilitates real-time, scalable, and accessible biological research, with applications ranging from healthcare to environmental science. Based in the UK, Oxford Nanopore has revolutionized the approach to molecular analysis by providing a direct and electric characterization of single molecules.
Ticker
£ONT
Sector
Health
Primary listing
LSE
Employees
1,314
Headquarters
Oxford, United Kingdom
Website
nanoporetech.com

ONT Metrics

BasicAdvanced
£2.3B
-
-£0.13
0.91
-

What the Analysts think about ONT

Analyst ratings (Buy, Hold, Sell) for Oxford Nanopore Technologies stock.
Analyst projections of the future price of Oxford Nanopore Technologies stock.

Bulls say / Bears say

Oxford Nanopore is showing operating leverage. First-half gross margin rose 400 basis points to 62.2%, while the adjusted EBITDA loss more than halved to £22.1 million as operating costs fell; management still expects adjusted EBITDA breakeven in FY27. (Financial News, ADVFN)
The strongest growth is coming from higher-value applied markets. Clinical revenue grew 35.4% and biopharma 25% in the first half, supporting the new target of more than $700 million of revenue by 2030 and an adjusted EBITDA margin above 15%. (Proactive Investors)
A new global diagnostics cross-licensing agreement adds a $20 million fee in the second half of 2026, £15 million of committed product purchases across 2027 and 2028, and potential royalties. This provides near-term support while creating an additional route to monetise Oxford Nanopore’s intellectual property. (DirectorsTalk Interviews, Business Quarter)
First-half revenue was below management expectations, with China down 16% and the Middle East down 14%; delayed American orders also hurt. The underlying full-year growth outlook is only 16% to 20% once new, potentially non-recurring opportunities are excluded. (Investegate, GenomeWeb)
Cash and liquid investments fell to £234.5 million from £302.8 million at the end of 2025, while the company remained loss-making. The runway is meaningful but finite, making any delay to the FY27 breakeven or FY28 free-cash-flow targets more damaging. (ADVFN)
The business still relies heavily on research customers, which account for roughly two-thirds of revenue, while research growth is slower than the targeted clinical and biopharma expansion. Those newer markets require validated workflows and face strong competition from larger sequencing companies with established customer relationships. (Business Quarter, Labiotech.eu)
Data summarised monthly by Lightyear AI. Last updated on 16 Sept 2026.

ONT Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

ONT Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing ONT

AllGBPUSDEUR
Funds
Fund name
Fund size
£ONT weighting
iShares FTSE 250£MIDD
£661M0.31%
Vanguard FTSE 250£VMID
£1.6B0.23%
iShares Healthcare Innovation$HEAL
$1.4B0.17%
iShares Healthcare Innovation€2B78
€1.2B0.17%
iShares Healthcare Innovation£DRDR
£1B0.17%
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by London Stock Exchange, through Infront.